• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Bone Biologics Corp

    11/14/24 7:19:34 PM ET
    $BBLG
    Industrial Specialties
    Health Care
    Get the next $BBLG alert in real time by email
    SC 13G/A 1 sch13g.htm
     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     

     
    SCHEDULE 13G
     
     
     
    Under the Securities Exchange Act of 1934
     
     
     
    (Amendment No. 2)*
     

     
    Bone Biologics Corporation
     
     
    (Name of Issuer)
     

     
    Common Stock, par value $0.001 per share
     
     
    (Title of Class of Securities)
     

     
    098070501
     
     
    (CUSIP Number)
     

     
    September 30, 2024
     
     
    (Date of Event which Requires Filing of this Statement)
     


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    [ ]            Rule 13d-1(b)
    [x]            Rule 13d-1(c)
    [ ]            Rule 13d-1(d)
    ___________________________________
    *  The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).



    1
    Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only)
    Lind Global Fund II LP
    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a)            [ ]
     
    (b)            [x]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
    Delaware

    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5  Sole Voting Power
    34,180
    6  Shared Voting Power
     
    0
    7  Sole Dispositive Power
     
    34,180
    8  Shared Dispositive Power
     
    0

    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    34,180(1)
     
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
     
     
    11
    Percent of Class Represented by Amount in Row (9)*
     
    1.9%
     
    12
    Type of Reporting Person (See Instructions)
    PN
     
    (1) The reporting person’s ownership consists of 34,180 warrants to purchase shares of common stock (the “Warrants”).


    1
    Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only)
    Lind Global Partners II LLC
    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a)            [ ]
     
    (b)            [x]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
    Delaware

    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5  Sole Voting Power
    34,180
    6  Shared Voting Power
     
    0
    7  Sole Dispositive Power
     
    34,180
    8  Shared Dispositive Power
     
    0

    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    34,180(1)
     
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
     
     
    11
    Percent of Class Represented by Amount in Row (9)*
     
    1.9%
     
    12
    Type of Reporting Person (See Instructions)
    OO
     
    (1) The reporting person’s ownership consists of 34,180 Warrants.

    1
    Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only)
     
    Jeff Easton
    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a)            [ ]
     
    (b)            [x]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
    United States

    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5  Sole Voting Power
     
    34,180
    6  Shared Voting Power
     
    0
    7  Sole Dispositive Power
     
    34,180
    8  Shared Dispositive Power
     
    0

    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
    34,180(1)
     
     
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
     
     
    11
    Percent of Class Represented by Amount in Row (9)*
     
    1.9%
     
    12
    Type of Reporting Person (See Instructions)
     
    IN
     

    (1) The reporting person’s ownership consists of 34,180 Warrants.


    Item 1.
    (a)
    Name of Issuer
     
     
    Bone Biologics Corporation
     
    (b)
    Address of Issuer’s Principal Executive Offices
     
     
    2 Burlington Woods Drive, Ste. 100
    Burlington, MA 01803

    Item 2.
    (a)
    Name of Person Filing
     
     
    This statement is filed by the following entities and individuals (collectively, referred to as the “Reporting Persons”):
     
    •    Lind Global Fund II LP, a Delaware limited partnership;
    •    Lind Global Partners II LLC, a Delaware limited liability company; and
    •    Jeff Easton, an individual and a citizen of the United States of America.
     
    Lind Global Partners II LLC, the general partner of Lind Global Fund II LP, may be deemed to have sole voting and dispositive power with respect to the shares held by Lind Global Fund II LP.
     
    Jeff Easton, the managing member of Lind Global Partners II LLC, may be deemed to have sole voting and dispositive power with respect to the shares held by Lind Global Fund II LP.
     
    (b)
    Address of Principal Business Office or, if none, Residence
     
     
    The address of the principal business office for each of the Reporting Persons is:
     
    444 Madison Ave, Floor 41
    New York, NY 10022
     
    (c)
    Citizenship
     
     
    See Row 4 of cover page for each Reporting Person.
     
    (d)
    Title of Class of Securities
     
     
    Common Stock, par value $0.001 per share
     
    (e)
    CUSIP Number
     
     
    098070501

    Item 3.
    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    Not applicable.
    Item 4.
    Ownership
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
    (a)
    Amount Beneficially Owned
     
     
     See Row 9 of cover page for each Reporting Person.
     
    (b)
    Percent of Class
     
     
    See Row 11 of cover page for each Reporting Person.
     

    (c)
    Number of shares as to which such person has:
     
     
    (i)
    sole power to vote or to direct the vote
       

    See Row 5 of cover page for each Reporting Person.
     
     
    (ii)
    shared power to vote or to direct the vote
       
     
    See Row 6 of cover page for each Reporting Person.
     
     
    (iii)
    sole power to dispose or to direct the disposition of
       

    See Row 7 of cover page for each Reporting Person.
     
     
    (iv)
    shared power to dispose or to direct the disposition of
       
     
    See Row 8 of cover page for each Reporting Person.
     

    Item 5.  Ownership of Five Percent or Less of a Class
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☒.
    Item 6.  Ownership of More than Five Percent on Behalf of Another Person
    Not applicable.
    Item 7.  Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company
    Not applicable.
    Item 8.
    Identification and Classification of Members of the Group
    Not applicable.
    Item 9.
    Notice of Dissolution of Group
    Not Applicable.
    Item 10.
    Certification
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    Exhibits
    Exhibit
    99.1            Joint Filing Application by and among the Reporting Persons

    SIGNATURE
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
    November 14, 2024
    LIND GLOBAL FUND II LP
       
    By:
     
    Lind Global Partners II LLC
     
     
    its General Partner
       
    By:
     
    /s/ Jeff Easton
    Name:
     
    Jeff Easton
    Title:
     
    Managing Member
     
    LIND GLOBAL PARTNERS II LLC
       
    By:
     
    /s/ Jeff Easton
    Name:
     
    Jeff Easton
    Title:
     
    Managing Member
     
    JEFF EASTON
     
    By:
     
    /s/ Jeff Easton

    Get the next $BBLG alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BBLG

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BBLG
    Leadership Updates

    Live Leadership Updates

    See more
    • Bone Biologics Appoints Phillip T. Meikle to its Board of Directors

      Brings 30+ years of commercial experience in the orthopedic and spine industry Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ:BBLG, BBLGW))), a developer of orthobiologic products for spine fusion markets, announces the appointment of Phillip T. Meikle to the Company's board of directors, effective immediately. Mr. Meikle succeeds Don R. Hankey, who retired from the Board following seven years of service. The number of directors of Bone Biologics remains at four. Mr. Meikle most recently was president and chief executive officer of Biosystems of New England, Inc., an orthopedic distribution company that he founded in 1992 and sold to Stryker Corporation in 2019. He

      10/21/24 8:00:00 AM ET
      $BBLG
      Industrial Specialties
      Health Care
    • Bone Biologics Appoints Healthcare Finance Veteran Robert E. Gagnon to Board of Directors

      Brings 20+ years of experience in finance and business operations at both public and private life sciences companies Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ:BBLG, BBLGW))), a developer of orthobiologic products for spine fusion markets, today announced that effective immediately Robert E. Gagnon has been named to the Company's board of directors. Mr. Gagnon fills the seat left by Erick Lucera, who has resigned effective upon Mr. Gagnon's appointment. The number of directors of Bone Biologics remains at four. Mr. Gagnon is currently chief financial officer of Remix Therapeutics, a clinical stage company focused on small molecule-mediated reprogramming of RN

      1/11/24 8:00:00 AM ET
      $BBLG
      Industrial Specialties
      Health Care

    $BBLG
    SEC Filings

    See more
    • SEC Form DEF 14A filed by Bone Biologics Corp

      DEF 14A - Bone Biologics Corp (0001419554) (Filer)

      4/23/25 8:00:36 AM ET
      $BBLG
      Industrial Specialties
      Health Care
    • SEC Form PRE 14A filed by Bone Biologics Corp

      PRE 14A - Bone Biologics Corp (0001419554) (Filer)

      4/11/25 5:05:39 PM ET
      $BBLG
      Industrial Specialties
      Health Care
    • SEC Form 8-K filed by Bone Biologics Corp

      8-K - Bone Biologics Corp (0001419554) (Filer)

      4/1/25 5:15:18 PM ET
      $BBLG
      Industrial Specialties
      Health Care

    $BBLG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Executive Officer Frelick Jeff

      4 - Bone Biologics Corp (0001419554) (Issuer)

      1/21/25 6:10:12 AM ET
      $BBLG
      Industrial Specialties
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Walsh Deina H

      4 - Bone Biologics Corp (0001419554) (Issuer)

      1/21/25 6:06:14 AM ET
      $BBLG
      Industrial Specialties
      Health Care
    • SEC Form 4 filed by Director Meikle Phillip Terry Ii

      4 - Bone Biologics Corp (0001419554) (Issuer)

      10/18/24 8:27:04 PM ET
      $BBLG
      Industrial Specialties
      Health Care

    $BBLG
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Bone Biologics Appoints Phillip T. Meikle to its Board of Directors

      Brings 30+ years of commercial experience in the orthopedic and spine industry Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ:BBLG, BBLGW))), a developer of orthobiologic products for spine fusion markets, announces the appointment of Phillip T. Meikle to the Company's board of directors, effective immediately. Mr. Meikle succeeds Don R. Hankey, who retired from the Board following seven years of service. The number of directors of Bone Biologics remains at four. Mr. Meikle most recently was president and chief executive officer of Biosystems of New England, Inc., an orthopedic distribution company that he founded in 1992 and sold to Stryker Corporation in 2019. He

      10/21/24 8:00:00 AM ET
      $BBLG
      Industrial Specialties
      Health Care
    • Bone Biologics Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference

      Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ:BBLG, BBLGW))), a developer of orthobiologic products for spine fusion markets, announces that Jeffrey Frelick, chief executive officer, will present virtually at the H.C. Wainwright 26th Annual Global Investment Conference being held September 9-11, 2024 in New York City. Bone Biologics' company presentation will be available here beginning on Monday, September 9th at 7:00 a.m. Eastern time. The presentation will be available on the company's website for a period of time here. Management is available throughout the conference for virtual one-on-one meetings. Institutional investors and industry professionals can regis

      9/4/24 8:00:00 AM ET
      $BBLG
      Industrial Specialties
      Health Care
    • Bone Biologics Announces Exercise of Warrants for $2.1 Million Gross Proceeds

      Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ:BBLG, BBLGW))), a developer of orthobiologic products for spine fusion markets, today announced that it has entered into a definitive agreement for the exercise of certain existing warrants to purchase an aggregate of 781,251 shares of its common stock having an exercise price of $2.43 per share, originally issued in March 2024. The issuance of the shares of common stock issuable upon exercise of the existing warrants is registered pursuant to an effective registration statement on Form S-1 (File No. 333-276771). H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. In consideration for t

      8/2/24 8:00:00 AM ET
      $BBLG
      Industrial Specialties
      Health Care

    $BBLG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Bone Biologics Corp

      SC 13G/A - Bone Biologics Corp (0001419554) (Subject)

      11/14/24 7:19:34 PM ET
      $BBLG
      Industrial Specialties
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Bone Biologics Corp

      SC 13G/A - Bone Biologics Corp (0001419554) (Subject)

      11/13/24 11:14:34 AM ET
      $BBLG
      Industrial Specialties
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Bone Biologics Corp

      SC 13G/A - Bone Biologics Corp (0001419554) (Subject)

      6/28/24 4:15:43 PM ET
      $BBLG
      Industrial Specialties
      Health Care